BIOMAT Database Logo BIOMAT Database Logo

[Experience with corticoid long-term therapy in multiple sclerosis]. 1967

E Muller, and M Kostakopoulos

UI MeSH Term Description Entries
D008297 Male Males
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D003348 Cortisone A naturally occurring glucocorticoid that has been used in replacement therapy for ADRENAL INSUFFICIENCY and as an anti-inflammatory agent. Cortisone itself is inactive; it is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726) 17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate,Adreson,Cortisone Acetate,Cortone Acetate
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

E Muller, and M Kostakopoulos
[Long-term corticoid therapy in dermatology].
January 1972, Archiv fur dermatologische Forschung,
E Muller, and M Kostakopoulos
Long-term survival experience of patients with multiple sclerosis.
January 1997, Journal of insurance medicine (New York, N.Y.),
E Muller, and M Kostakopoulos
Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
September 2006, Autoimmunity,
E Muller, and M Kostakopoulos
Long-term experience with induction treatment regimens in multiple sclerosis.
February 2009, Journal of the neurological sciences,
E Muller, and M Kostakopoulos
[Long-term steroid therapy in multiple sclerosis].
January 1992, Neurologia i neurochirurgia polska,
E Muller, and M Kostakopoulos
[Long-term corticoid treatment of disseminated cerebrospinal sclerosis].
May 1978, Ceskoslovenska neurologie a neurochirurgie,
E Muller, and M Kostakopoulos
[Asthma and long-term corticoid therapy].
January 1963, Journal francais de medecine et chirurgie thoraciques,
E Muller, and M Kostakopoulos
[Beclomethasone dipropionate in long-term corticoid therapy].
January 1975, Le Poumon et le coeur,
E Muller, and M Kostakopoulos
Experience with long-term rituximab use in a multiple sclerosis clinic.
January 2016, Multiple sclerosis journal - experimental, translational and clinical,
E Muller, and M Kostakopoulos
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
September 2005, Journal of neurology,
Copied contents to your clipboard!